Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, is launching a nationwide rollout of Enjuvia, a synthetic estrogen tablet to treat moderate-to-severe menopausal symptoms.
A plant-derived formulation, Enjuvia contains a blend of 10 synthetic estrogenic substances including delta 8,9 - dehydroesterone sulfate (DHES). Enjuvia tablets are available in a variety of dosage strengths
The company said it is shipping the product to pharmacies across the country and will begin other promotions targeting health care providers in mid-May.
"Enjuvia is a new option for American women electing, in consultation with their physicians, to use prescription hormone therapy and provides them with a low dose alternative to treat the moderate-to-severe vasomotor symptoms of menopause," said Bruce L. Downey, Barr's Chairman and Chief Executive Officer.
"Enjuvia is an important new treatment option that has been proven to significantly reduce the frequency and severity of vasomotor symptoms (hot flashes and night sweats), which can impact a woman's ability to function," said Dr. David Portman, Director of the Columbus Center for Women's Health Research in Columbus, Ohio.
"Women suffering with menopausal symptoms should talk to their healthcare professional about finding a low dose hormone therapy that's right for them," Portman added.
Enjuvia uses a unique delivery system that provides slow release of estrogens over several hours.
|
HOME PAGE
